Median PFS-AR varied across different breast cancer subtypes: 6.7 months for luminal A-like, 12.3 months for luminal B-like, 12.7 months for HER2+, and 14.7 months for triple-negative subtypes (p = 0.81) (Figure A5). This evidence concerns the gene ERBB2 and breast cancer.